Japan Biologics Market Size & Outlook, 2024-2030
Japan biologics market, 2018-2030 (US$M)
Related Markets
Japan biologics market highlights
- The Japan biologics market generated a revenue of USD 38.6 million in 2024 and is expected to reach USD 68.5 million by 2030.
- The Japan market is expected to grow at a CAGR of 10% from 2025 to 2030.
- In terms of segment, microbial was the largest revenue generating biologics source in 2024.
- Others Biologics Source is the most lucrative biologics source segment registering the fastest growth during the forecast period.
Biologics market data book summary
| Market revenue in 2024 | USD 38.6 million |
| Market revenue in 2030 | USD 68.5 million |
| Growth rate | 10% (CAGR from 2024 to 2030) |
| Largest segment | Microbial |
| Fastest growing segment | Others Biologics Source |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Microbial, Mammalian, Others Biologics Source |
| Key market players worldwide | Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, Japan accounted for 6.8% of the global biologics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan biologics market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 35.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Market Scope
Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan biologics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics market will help companies and investors design strategic landscapes.
Microbial was the largest segment with a revenue share of 58.29% in 2024. Horizon Databook has segmented the Japan biologics market based on microbial, mammalian, others biologics source covering the revenue growth of each sub-segment from 2018 to 2030.
Japan's biologics market is driven by its strong life science base and a favorable market environment. Also, the presence of efficient regulatory processes and effective IP protection in the country is anticipated to influence the growth of the biologics market in the coming years.
The presence of the Pharmaceuticals and Medical Devices Agency (PMDA) which is involved in reviewing and auditing of drugs including biologics is anticipated to dramatically impact the Japanese market of biologics.
Moreover, Japanese government is adopting industrial policies to support biologics development and to overcome the challenges faced by biologic manufacturers such as growth in biosimilar products. In addition, most innovative biologics are reimbursed in the region owing to its relatively large domestic market.
Reasons to subscribe to Japan biologics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan biologics market databook
-
Our clientele includes a mix of biologics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan biologics market , including forecasts for subscribers. This country databook contains high-level insights into Japan biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan Biologics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
